Free Trial
NASDAQ:ASBP

Aspire Biopharma Q1 2026 Earnings Report

Aspire Biopharma logo
$8.88 +0.10 (+1.14%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$8.95 +0.07 (+0.79%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aspire Biopharma EPS Results

Actual EPS
-$20.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aspire Biopharma Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aspire Biopharma Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Aspire Biopharma Earnings Headlines

Comparing Aspire Biopharma (NASDAQ:ASBP) and Aptiv (NYSE:APTV)
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.tc pixel
See More Aspire Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aspire Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aspire Biopharma and other key companies, straight to your email.

About Aspire Biopharma

Aspire Biopharma (NASDAQ:ASBP), Inc. is a clinical-stage biopharmaceutical company developing drug-delivery products based on proprietary oral thin-film technology. Its platform is designed to deliver medication through the mouth without requiring water or conventional swallowing, with the goal of enabling rapid absorption and improving ease of use.

The company’s lead development program is an orally administered aspirin product intended for potential use in acute cardiovascular situations, where rapid delivery may be important. Aspire Biopharma is also evaluating additional applications of its delivery platform for other pharmaceutical compounds and therapeutic areas.

The company’s products remain under development and require regulatory review and approval before they can be marketed. Aspire Biopharma became a publicly traded company following a business combination with PowerUp Acquisition Corp. in 2024.

View Aspire Biopharma Profile